Background. We assessed the morbidity of herpesviruses in patients with type 1 diabetes mellitus (T1D) enrolled in immunosuppressive treatment studies.
The use of immunosuppressive therapy for the treatment of autoimmune diseases is rapidly increasing. This approach is widely utilized for rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease, but it is only in the experimental stage for the treatment of type 1 diabetes mellitus (T1D). The efficacy of cyclosporine A, anti-CD3, and anti-CD20 monoclonal antibodies to prevent, halt, or slow progression of T1D have been investigated [1] [2] [3] . Although these interventions have not achieved a long-lasting therapeutic effect, they have shown temporary preservation of pancreatic β-cell function. Accordingly, there are ongoing efforts to evaluate additional agents in order to identify regimens that might result in long-lasting benefits. In this light, we recently completed a prospective, randomized, multicenter clinical trial evaluating the efficacy of mycophenolate mofetil (MMF) with or without daclizumab (DZB) as treatment for new-onset T1D [4] .
The use of immunosuppressive agents raises concerns for potential infectious complications [5] [6] [7] . A particular focus of this concern is the impact on herpesviral infections. The Herpesviridae family is characterized by life-long infection through the establishment of latency. Notorious pathogens are Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus 1 and 2 (HSV1 and HSV2), and varicella zoster virus (VZV). Infection due to these viruses ( primary or reactivation/reinfection) has been associated with increased morbidity and potentially mortality in immunosuppressed patients [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . EBV infection in particular has been associated with the development of lymphoproliferative disease including lymphoma [6, 12, [19] [20] [21] [22] [23] [24] [25] . Accordingly, monitoring acquisition and reactivation of herpesviruses provides important safety data when evaluating potential immunosuppressive regimens.
This report reviews results of prospective serologic, virologic, and clinical monitoring for infection and disease due to herpesvirus infections in patients with new-onset T1D participating in a trial of MMF and DZB [4] .
SUBJECTS AND METHODS

Study Description
The was a 4-arm, randomized, double-masked, placebo-controlled clinical trial conducted by the Type 1 Diabetes TrialNet at 13 sites in subjects aged 8-45 years with recognized T1D for <3 months [4] . The protocol was approved by the data and safety monitoring board (DSMB) and local institutional review boards. All subjects or caretakers provided written informed consent and/or assent.
Subjects were randomized to receive MMF with DZB (both from Roche Pharmaceuticals; DZB DZB or placebo was given by intravenous infusion at study day 0 and 2 weeks later at a dose of 1 mg/kg. All subjects were followed for ≥2 years. Per protocol, study drugs were suspended in subjects who developed clinical or laboratory evidence of EBV or CMV primary infections or reactivations.
Laboratory Studies
Subjects had CMV, EBV, HSV, and VZV serologic evaluations and EBV and CMV polymerase chain reaction (PCR) at baseline. CMV and EBV infections were monitored weekly by serology and PCR during the first 4 weeks of study and biweekly during the subsequent 4 weeks. Thereafter, EBV-and CMVseronegative subjects were followed monthly, and EBV-and CMV-seropositive subjects were followed at 3-month intervals. Per protocol, if EBV or CMV viremia developed, the PCR was repeated weekly during the first 4 weeks, biweekly during the subsequent 4 weeks, and monthly thereafter until it resolved.
Real-Time Quantitative EBV DNA PCR A validated quantitative EBV DNA PCR in whole blood was performed as previously described [26] . The lower limit of detection was 100 copies/mL and the dynamic range was ≥500 DNA copies/mL.
Real-Time Quantitative CMV DNA PCR Real-time quantitative CMV DNA PCR was performed following the same protocol described for EBV DNA PCR, but with the following primers and probes from Eco R1 region D: GGCAGCTATCGTGACTGG and GATCCGACCCATTGTC TAAG and probes CGACGGTGATTCGTGGTCGT-fluorescein and LC Red640 -CCAACTGGTGCTGCCGGTCG-phosphate elongation block. The analytical sensitivity was ≥100 DNA copies/mL and dynamic range ≥500 copies/mL. 
Clinical Data Collection and Management
New signs and symptoms were spontaneously reported by the subjects or guardians, but also solicited at each study visit for the interval between visits. Intercurrent illnesses were reported through the adverse event reporting system. Each event was investigated by the clinical site personnel as per local standard of care or in consultation with the T1D TrialNet Infectious Diseases group. In addition, if a subject developed CMV or EBV viremia confirmed by 2 sequential positive PCR results, treatment was suspended until the viremia disappeared as defined by 2 sequential negative PCR results. All adverse events were reviewed by the medical monitor in a treatment-masked fashion and classified according to the Common Terminology Criteria for Adverse Events version 3 (http://ctep.cancer.gov/protocolDevelopment/electronic_ applications/ctc.htm). The DSMB received quarterly summary safety reports.
Statistical Analysis
Descriptive statistics, t test (or the Wilcoxon rank sum test), and Fisher exact test were used to analyze the characteristics of the 4 cohorts. The Anderson-Darling statistic was used to assess normality; where appropriate, data were log transformed prior to testing. The area under the concentrationtime curve (AUC) was calculated using the trapezoidal rule. For seroconverters who did not have a detectable EBV load (<100 copies/mL), a value of 99 was assigned for the calculation of the AUC. SAS G2 software was used in all analyses.
RESULTS
Demographic and Other Characteristics of the Study Population
The 126 subjects in the study had similar demographic characteristics across the 4 treatment arms (Table 1) , including median age of 15 years (range, 9-46 years); 60% male sex; and 93% white race. At baseline, 55% were seropositive for EBV, 32% for CMV, 19% for HSV, and 84% for VZV. All subjects received the DZB or placebo infusions. The mean duration of MMF or treatment placebo was 20 months (SD, 6 months) months and the mean duration of follow-up on study was 23 months (SD, 4 months). The treatment did not have a significant impact on the progression of T1D.
EBV Primary Infections and Reactivations
There were 8 reports of mononucleosis-like syndromes. Two occurred in subjects with primary EBV infection and one in a subject who was experiencing an EBV reactivation. The remaining 5 subjects did not have any evidence of an associated active EBV infection by serology or PCR. All clinical symptoms in subjects with EBV-associated mono-like syndromes resolved without therapeutic interventions. However, study medication was withheld per protocol as noted above.
Primary infections were documented by positive EBV PCR in 9 of 57 subjects who were EBV-seronegative at baseline: Table 2 ). The magnitude of the viremia measured by AUC varied from 12.3 to 16.3 log 10 EBV DNA copies/mL and did not appear grossly different among treatment groups. Eight of the 9 subjects had ≥1 serum sample tested for EBV-specific antibodies after the positive PCR result. Of the 8 subjects with . At the time of the reactivation, 8 subjects were receiving active drug. Of the remaining 14, 9 were on placebo and 5 had already completed or interrupted treatment and were being followed off medication. In subjects still on treatment (active or placebo), the study medication was stopped after 2 consecutive positive EBV PCR results. Nevertheless, HSV episode diagnosed for the first time during the study did not have baseline serology data. The remaining 8 subjects had recurrent orolabial HSV. The incidence of recurrent HSV infections was not significantly different among the 4 treatment groups (P = .25, Fisher exact test). Four subjects received antiviral therapy including 2 subjects who also were prescribed prophylactic antivirals due to multiple recurrences. The other episodes resolved without antiviral treatment. One subject with multiple recurrences also stopped study medication during one of the HSV recurrences.
VZV Reactivations
Of 121 subjects, 102 (84%) were VZV-seropositive at baseline.
There was an episode of herpes zoster in this study documented in a DZB -MMF -recipient. The subject had a self-limited rash that resolved after 7 days of therapy with valacyclovir and was not complicated by postherpetic neuralgia. A VZV-seropositive, HSV-seronegative subject in the DZB − MMF + group experienced an episode of Bell's palsy, which is deemed to be sometimes due to HSV or VZV reactivation [27, 28] . The subject was treated with valacyclovir by his primary care physician without any specific evidence of VZV reactivation. Clinical symptoms improved on therapy.
DISCUSSION
We did not find any significant morbidity attributable to herpesviruses in individuals with early onset T1D treated with MMF and/or DZB despite having active surveillance in place for the potential development of these infections. This finding was reassuring in view of the rapidly growing use of immunosuppressive regimens to treat and/or prevent inflammatory and autoimmune disorders including T1D. However, our sample size was relatively small. It is also important to note that the combination of MMF and DZB did not have a significant effect on the progression of diabetes [4] , while limited success has been reported with other immunosuppressive regimens [1] [2] [3] 29] . One of the potential explanations for the therapeutic failure of MMF/DZB is that this regimen is not potent enough to modulate the immune response against the pancreatic islet cells or did not target the mechanisms relevant for T1D. The corollary is that more potent regimens may be associated with a higher incidence of opportunistic infections. EBV primary infections and reactivations were closely monitored due to the oncogenic potential of this virus and the established role of immunosuppression on EBV-associated morbidity and mortality in other populations. The 9 EBV primary infections (2 symptomatic) detected in this study were roughly equally distributed across treatment groups. Although the numbers were too small for a formal statistical analysis, there were no gross differences in the course of the primary infections across treatment groups. All subjects with serologic follow-up after the primary EBV infection developed IgG anti-VCA antibodies, suggesting that the ability to mount humoral immune responses was not grossly affected by any of the drug combinations. IgM responses were demonstrated in 75% of the subjects with serologic follow-up, which is in agreement with the frequency of IgM responses in immunocompetent individuals with EBV-associated infectious mononucleosis [30, 31] . All subjects with ≥1 month of follow-up after the first positive PCR result developed anti-EBNA antibodies. Lack of seroconversion to EBNA has been associated with increased risk of posttransplant lymphoproliferative disorder in the transplant population [12, 15, 16, 32] . Hence, it was reassuring to document EBNA seroconversion in all the subjects with primary EBV infection who had an adequate length of follow-up in this study.
EBV reactivations occurred in 30% of the EBV-seropositive subjects; the rate of reactivation was similar across treatment groups. Asymptomatic EBV reactivations have been frequently described in healthy blood donor and other immunocompetent individuals [13, 33] . However, the studies in healthy volunteers provided cross-sectional information on EBV reactivation, whereas our data were longitudinal, making it difficult to compare the rates of EBV reactivation in our subjects with T1D with those reported in the general population. It is noteworthy that a rate of EBV reactivation similar to the one in this study was found in T1D placebo recipients enrolled in other TrialNet intervention studies ( J. Kroll et al, manuscript in preparation). The viral loads during reactivations could vary in magnitude by >1 log 10 between sequential visits, but overall they did not appreciably differ from EBV viral loads measured in transplant recipients in the same laboratory [26] . The duration of reactivations was also highly variable from a single visit (confirmed with a second test within the following week) to ≥24 months. Only 1 subject had symptoms consistent with infectious mononucleosis during an EBV reactivation. However, because the reactivation started 8 months before the subject became symptomatic and extended for another 16 months after symptoms resolved, it is unclear whether EBV was truly responsible for this adverse event. Previous studies using anti-CD3 humanized mouse monoclonal antibodies to prevent progression of early onset T1D showed infectious mononucleosis-like symptoms in 75% of the active treatment recipients [1] . However, in our study, perhaps due to the lower intensity of the immunosuppression, EBV reactivations were not associated with significant clinical consequences regardless of treatment group.
Although there were no clinical differences among treatment arms, the DZB + MMF + subjects had protracted viremia and higher copy numbers of circulating EBV DNA compared with the DZB -MMF -controls. This suggests that the 2-drug combination had an immunologic effect, albeit modest. There were no CMV reactivations documented by CMV DNA PCR in whole blood. There were 4 CMV primary infections during the study, all of which were asymptomatic and were not accompanied by viremia. Although it is possible that brief transient episodes of viremia occurred between scheduled assays, overall, our findings indicate that the immunosuppression in the MMF and/or DZB recipients was not intensive enough to cause CMV-associated morbidity.
Herpes zoster is a common complication of cell-mediated immune suppression. However, in this study, the incidence of herpes zoster was in line with the 0.15 per 100 person-years incidence of herpes zoster reported in the age-matched general population (10-19 years) [34] . Taken together, the data indicate that the rate of symptomatic VZV reactivations was not adversely affected by treatment or T1D in this small study.
HSV reactivations seemed to be clustered in the DZB + MMF + and DZB − MMF + arms, but the differences did not reach statistical significance. Furthermore, reactivation episodes that were not treated with antivirals showed normal healing and episodes of primary or first nonprimary HSV infections subsided after 3-5 days of antiviral therapy. The data indicate that although HSV symptomatic infections were not uncommon in this population, their morbidity did not appear to differ from that of HSV disease in immunocompetent individuals. The MMF/DZB study was the first intervention trial using immunosuppressive therapy conducted by the T1D TrialNet Study Group. In the absence of extensive data regarding the clinical course of herpesvirus infections in T1D patients treated with immunosuppressive drugs, it was deemed important to closely monitor these infections, particularly EBV and CMV. Retrospectively, the MMF/DZB combination was safe and the cost of the monitor was higher than warranted. Nevertheless, this study provided new data on the natural history of herpesvirus infections in T1D individuals with or without MMF/DZB treatment, including the high frequency of EBV reactivations in double-placebo recipients, that will be useful in planning viral monitors in future studies.
Notes
